Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada. Show more
Location: 322 11th Avenue SW, Calgary, AB, T2R 0C5, Canada | Website: https://oncolyticsbiotech.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
139.7M
52 Wk Range
$0.33 - $1.53
Previous Close
$1.42
Open
$1.42
Volume
904,360
Day Range
$1.36 - $1.42
Enterprise Value
133.9M
Cash
14.63M
Avg Qtr Burn
-6.162M
Insider Ownership
0.00%
Institutional Own.
0.09%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pelareorep + gemcitabine, nab-paclitaxel, atezolizumab Details Pancreatic cancer | Phase 3 Initiation | |
Pelareorep + paclitaxel + avelumab (Bavencio®) Details Breast cancer | Phase 3 Initiation | |
Pelareorep + Retifanlimab Details Triple-negative breast cancer | Phase 2 Update | |
Pelareorep + modified FOLFIRINOX +/- atezolizumab Details Metastatic pancreatic cancer (mPDAC) | Phase 1/2 Data readout | |
Pelareorep + Atezolizumab (Tecentriq) Details 2L Squamous Cell Carcinoma of Anal Canal (SCAC) | Phase 1/2 Data readout | |
Pelareorep + Keytruda® Details Pancreatic cancer, Sarcoma | Failed Discontinued | |
Pelareorep +/- Atezolizumab Details Cancer, Breast cancer | Failed Discontinued |